Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  liposome-encapsulated doxorubicin citrate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-12 of 12 for your search:
Start Over
Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 70 and over
Sponsor: Other
Protocol IDs: GERICO11/PACS10, 2011-004744-22, UC-0103/1102, NCT01564056
8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer
Phase: Phase III
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BOOG 2010-02 Stop&Go study, NTR2589, NCT01935492
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GBG 84, NCT02125344
The Myocet/Lapatinib Study. ICORG 10-03, V5
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ICORG 10-03, NCT01495884
Rituximab, Cyclophosphamide, Vincristine Sulfate, and Prednisone With or Without Liposome-Encapsulated Doxorubicin Citrate in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Other
Protocol IDs: CDR0000636032, IB-FRAIL06, INCA-RECF0892, IB-2008-25, EUDRACT-2008-001506-16, FRAIL 06, NCT00911183
Ciclophosphamide, Vincristine, Myocet and Prednisone, With Rituximab in 1st-Line Treatment for Patients With No-Hodgkin B Lymphoma and Cardiovascular (CV) Risk
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: ADOPEH-LINFMYO-2007, NCT00849355
Myocet Plus Endoxan for Older Patients With Breast Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 70 and over
Sponsor: Other
Protocol IDs: CT/08.32, NCT01120171
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: VICC BMT 1020, NCT01215344
Study of Myocet Plus Cyclophosphamide Plus Metformin Versus Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Cancer Patients
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: IRST174.04, 2009-014662-26, NCT01885013
Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 60 and over
Sponsor: Other
Protocol IDs: GEL-R-COMP-2013, NCT02012088
History of the KSHV Inflammatory Cytokine Syndrome (KICS)
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110220, 11-C-0220, NCT01419561
Start Over